Vorasidenib: Difference between revisions

Voradisenib
Clinical data
License data	US DailyMed: Vorasidenib;
Drug class	Antineoplastic agent
Identifiers
	IUPAC name 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine;
CAS Number	1644545-52-7;
PubChem CID	117817422;
IUPHAR/BPS	10663;
DrugBank	DB17097;
ChemSpider	64835242;
UNII	789Q85GA8P;
ChEMBL	ChEMBL4279047;
Chemical and physical data
Formula	C14H13ClF6N6
Molar mass	414.74 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F;
	InChI InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1; Key:QCZAWDGAVJMPTA-RNFRBKRXSA-N;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 10:02, 7 September 2023

Vorasidenib is an anti-cancer medication for the treatment of low-grade Glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer.^[1] In a phase-III-trial it was shown to prolong progression-free survival in patients with IDH1- or IDH2-Mutant Low-Grade Glioma.^[2]

References

^ "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.{{cite web}}: CS1 maint: url-status (link)
^ Ingo K. Mellinghoff; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690

[Vorasidenib-1] "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.{{cite web}}: CS1 maint: url-status (link)

[Mellinghoff23-2] Ingo K. Mellinghoff; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690

[1]

[2]

@@ Line 1: / Line 1: @@
 {{Short description|Anti-cancer medication}}
+{{Orphan|date=September 2023}}
 {{Draft topics|chemistry|medicine-and-health}}
 {{AfC topic|stem}}
@@ Line 28: / Line 30: @@
 | ATC_prefix        =
 | ATC_suffix        =
 | ATC_supplemental  =
 <!-- Legal status -->
@@ Line 49: / Line 51: @@
 | legal_UN =
 | legal_UN_comment =
 | legal_status      =
 <!-- Pharmacokinetic data -->
@@ Line 59: / Line 61: @@
 | elimination_half-life =
 | duration_of_action =
 | excretion         =
 <!-- Identifiers -->
@@ Line 75: / Line 77: @@
 | NIAID_ChemDB      =
 | PDB_ligand        =
 | synonyms          =
 <!-- Chemical and physical data -->
@@ Line 95: / Line 97: @@
 }}
-'''Vorasidenib''' is an [[anti-cancer medication]] for the treatment of low-grade [[Glioma]]. It is a [[targeted therapy|small molecule inhibitor]] of [[IDH1|isocitrate dehydrogenase-1]] (IDH1) and [[IDH2|isocitrate dehydrogenase-2]] (IDH2), which are mutated in several forms of [[cancer]]. <ref name="Vorasidenib">{{cite web | title=Vorasidenib compound summary | website=pubchem | date=2 September 2023 | url=https://pubchem.ncbi.nlm.nih.gov/compound/Vorasidenib | access-date=6 September 2023| url-status=live }}</ref>In a phase-III-trial it was shown to prolong progression-free survival in patients with IDH1- or IDH2-Mutant Low-Grade Glioma.<ref name = "Mellinghoff23">{{citation|author=Ingo K. Mellinghoff|display-authors=et al.|date=2023-08-17|doi=10.1056/NEJMoa2304194|issue=7|pages=389–601|periodical=New England Journal of Medicine|pmc=5900343|pmid=29670690|title=Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma|volume=389}}<!-- auto-translated by Module:CS1 translator --></ref>
+'''Vorasidenib''' is an [[anti-cancer medication]] for the treatment of low-grade [[Glioma]]. It is a [[targeted therapy|small molecule inhibitor]] of [[IDH1|isocitrate dehydrogenase-1]] (IDH1) and [[IDH2|isocitrate dehydrogenase-2]] (IDH2), which are mutated in several forms of [[cancer]].<ref name="Vorasidenib">{{cite web | title=Vorasidenib compound summary | website=pubchem | date=2 September 2023 | url=https://pubchem.ncbi.nlm.nih.gov/compound/Vorasidenib | access-date=6 September 2023| url-status=live }}</ref> In a phase-III-trial it was shown to prolong progression-free survival in patients with IDH1- or IDH2-Mutant Low-Grade Glioma.<ref name = "Mellinghoff23">{{citation|author=Ingo K. Mellinghoff|display-authors=et al.|date=2023-08-17|doi=10.1056/NEJMoa2304194|issue=7|pages=389–601|periodical=New England Journal of Medicine|pmc=5900343|pmid=29670690|title=Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma|volume=389}}<!-- auto-translated by Module:CS1 translator --></ref>
 == References ==